HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Complete response after neoadjuvant therapy : How certain is the pathology?]

Abstract
Histopathologic evaluation of tumors after neoadjuvant therapy is performed by tumor regression grading (TRG) systems, which reflect the proportion of vital residual primary tumor in relation to the previous total tumor. The World Health Organization (WHO) tumor grading is replaced by TRG in tumor classification. The histopathological work-up of a tumor is based on the criteria of the TNM classification even after neoadjuvant therapy. A uniform TRG does not exist. For various tumors TRGs based on the tumor entity have been established, consisting of a 3-stage or 5‑stage grading system. Complete histopathological tumor regression is only present if no vital tumor cells are detectable in the histopathological examination of the primary surgical specimens (primary tumor and accompanying locoregional lymph nodes) and there are no distant metastases.
AuthorsIris Tischoff, Andrea Tannapfel
JournalDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen (Chirurg) Vol. 93 Issue 2 Pg. 115-122 (Feb 2022) ISSN: 1433-0385 [Electronic] Germany
Vernacular TitleKomplettresponse nach neoadjuvanter Therapie : Wie sicher ist die Pathologie?
PMID34613440 (Publication Type: Journal Article, Review)
Copyright© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Topics
  • Lymph Nodes
  • Neoadjuvant Therapy
  • Neoplasm Grading
  • Neoplasm Staging
  • Prognosis
  • Remission Induction
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: